Clinical Trials Logo

Filter by:
NCT ID: NCT01395147 Completed - Clinical trials for Major Depressive Disorder

Long-Term Extension Study of Lu AA21004 in Participants With Major Depressive Disorder

Start date: July 2011
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of Lu AA21004 in participants with major depressive disorder after completion of an 8-week double-blind treatment period in a preceding study (Lu AA21004/CCT-003; NCT01355081).

NCT ID: NCT01394653 Completed - Healthy Clinical Trials

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet and Conventional Tablet Under With Water Intake

Start date: July 2011
Phase: Phase 1
Study type: Interventional

A study to compare time-course changes of plasma concentration of YM060 orally-disintegrating tablet with those of conventional tablet. Tablets will be administered with water.

NCT ID: NCT01393951 Completed - Healthy Clinical Trials

A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers

Start date: May 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is designed as a blinded, randomized and parallel group study to investigate the clinically recommended dosage for ASP7374 based on the comparison of the immunogenicity and safety among two doses of subcutaneous ASP7374 and one dose of intramuscular ASP7374 in healthy adults.

NCT ID: NCT01393899 Completed - Crohn's Disease Clinical Trials

The Safety And Efficacy Of Maintenance Therapy With CP-690,550

Start date: March 2012
Phase: Phase 2
Study type: Interventional

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI<150) at Week 8.

NCT ID: NCT01393626 Completed - Crohn's Disease Clinical Trials

A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease

Start date: October 2011
Phase: Phase 2
Study type: Interventional

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).

NCT ID: NCT01392924 Completed - Neoplasm Malignant Clinical Trials

Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid Tumors

Start date: August 2011
Phase: Phase 1
Study type: Interventional

Primary Objective: - To confirm safety and tolerability of global recommended phase three dose (RPTD) of SAR245408 tablets when administered on continuous once daily dosing (CDD) in patients with solid tumors. Secondary Objectives: - To evaluate the plasma pharmacokinetics (PK) of daily oral administration of SAR245408 in CDD treatment schedule in patients with solid tumors. - To gather preliminary efficacy data after repeated administration of SAR245408 in patients with solid tumors.

NCT ID: NCT01392820 Completed - Healthy Clinical Trials

A Study of Single and Multiple Ascending Doses of TC-5214 in Japanese Healthy Elderly Male and Female Volunteers

Start date: July 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess safety, tolerability and pharmacokinetics of TC-5214 in elderly healthy Japanese volunteers.

NCT ID: NCT01392794 Completed - Healthy Clinical Trials

A Study to Compare Oral Absorption of YM060 Between Orally-disintegrating Tablet (Without Water) and Conventional Tablet

Start date: April 2011
Phase: Phase 1
Study type: Interventional

A study to compare time-course changes of plasma concentration of YM060 after intake of conventional tablet and orally-disintegrating tablet. Orally-disintegrating tablets will be administered without water.

NCT ID: NCT01392547 Completed - Clinical trials for Congenital Bleeding Disorder

Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors

adeptâ„¢2
Start date: July 2011
Phase: Phase 3
Study type: Interventional

This trial is conducted globally. The purpose of this trial is to confirm the efficacy and safety of NNC 0078-0000-0007 in patients with congenital haemophilia and inhibitors.

NCT ID: NCT01392443 Completed - Clinical trials for Primary Myelofibrosis (MF)

Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

Start date: October 14, 2010
Phase: Phase 2
Study type: Interventional

The objective of this study was to determine the efficacy of INC424 as assessed by reduction in spleen volume in patients with primary myelofibrosis (MF), post-polycythemia vera (PV) MF, or post-essential thrombocythemia (ET) MF. The safety and tolerability of INC424 and the effects of INC424 on patient reported outcomes and the duration of response as assessed by reduction in spleen volume was also assessed.